RS Crum Inc’s Inhibrx, Inc. Common Stock INBX Stock Holding History

RS Crum Inc’s Portfolio INBX Stock Details INBX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-14,119	Closed	-$494K	–	96
2024 Q1	$494K	Sell	14,119 -540	-4%	-$19.7K	0.13%	47
2023 Q4	$557K	Hold	14,659	–	–	0.17%	41
2023 Q3	$269K	Hold	14,659	–	–	0.1%	67
2023 Q2	$381K	Hold	14,659	–	–	0.14%	51
2023 Q1	$277K	Hold	14,659	–	–	0.11%	62
2022 Q4	$361K	Hold	14,659	–	–	0.17%	54
2022 Q3	$263K	Buy	+14,659	New	+$264K	0.14%	59
2022 Q2	–	Sell	-14,659	Closed	-$327K	–	80
2022 Q1	$327K	Buy	+14,659	New	+$374K	0.19%	54

Other funds holding INBX

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

RS Crum Inc's INBX Position: Q2 2024 in Review

RS Crum Inc sold out of Inhibrx, Inc. Common Stock (INBX) in Q2 2024, closing a stake of 14,119 shares — an estimated $494K sold.

RS Crum Inc first reported a position in INBX in Q1 2022 and held it in 8 quarters. The position peaked at $557K in Q4 2023. 2 funds tracked by Wall St. Rank hold INBX as of Q2 2024.

RS Crum Inc reported no remaining Inhibrx, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
RS Crum Inc sold 14,119 Inhibrx, Inc. Common Stock shares in Q2 2024, an estimated $494K.
RS Crum Inc first reported a position in Inhibrx, Inc. Common Stock in Q1 2022 and held it in 8 quarters.
RS Crum Inc's Inhibrx, Inc. Common Stock position peaked at $557K in Q4 2023.
2 funds tracked by Wall St. Rank held Inhibrx, Inc. Common Stock as of Q2 2024.

Based on RS Crum Inc's 13F filing for Q2 2024, filed 8 Aug 2024.